These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
6. Novel use of a lipid-lowering fibrate medication to prevent nicotine reward and relapse: preclinical findings. Panlilio LV; Justinova Z; Mascia P; Pistis M; Luchicchi A; Lecca S; Barnes C; Redhi GH; Adair J; Heishman SJ; Yasar S; Aliczki M; Haller J; Goldberg SR Neuropsychopharmacology; 2012 Jul; 37(8):1838-47. PubMed ID: 22453137 [TBL] [Abstract][Full Text] [Related]
7. Inhibition of N-acylethanolamine acid amidase reduces nicotine-induced dopamine activation and reward. Sagheddu C; Scherma M; Congiu M; Fadda P; Carta G; Banni S; Wood JT; Makriyannis A; Malamas MS; Pistis M Neuropharmacology; 2019 Jan; 144():327-336. PubMed ID: 30439418 [TBL] [Abstract][Full Text] [Related]
8. Metabotropic glutamate receptor 5 antagonist 2-methyl-6-(phenylethynyl)pyridine (MPEP) microinfusions into the nucleus accumbens shell or ventral tegmental area attenuate the reinforcing effects of nicotine in rats. D'Souza MS; Markou A Neuropharmacology; 2011 Dec; 61(8):1399-405. PubMed ID: 21896278 [TBL] [Abstract][Full Text] [Related]
9. Inhibition of anandamide hydrolysis by cyclohexyl carbamic acid 3'-carbamoyl-3-yl ester (URB597) reverses abuse-related behavioral and neurochemical effects of nicotine in rats. Scherma M; Panlilio LV; Fadda P; Fattore L; Gamaleddin I; Le Foll B; Justinová Z; Mikics E; Haller J; Medalie J; Stroik J; Barnes C; Yasar S; Tanda G; Piomelli D; Fratta W; Goldberg SR J Pharmacol Exp Ther; 2008 Nov; 327(2):482-90. PubMed ID: 18725543 [TBL] [Abstract][Full Text] [Related]
10. Wy14643 improves vascular function in the aorta of the spontaneously hypertensive rat mainly by activating peroxisome proliferator-activated receptors alpha. Qu C; Leung SW; Vanhoutte PM; Man RY Eur J Pharmacol; 2012 Dec; 696(1-3):101-10. PubMed ID: 23022336 [TBL] [Abstract][Full Text] [Related]
11. Noradrenergic alpha1 receptors as a novel target for the treatment of nicotine addiction. Forget B; Wertheim C; Mascia P; Pushparaj A; Goldberg SR; Le Foll B Neuropsychopharmacology; 2010 Jul; 35(8):1751-60. PubMed ID: 20357760 [TBL] [Abstract][Full Text] [Related]
12. Local alpha-bungarotoxin-sensitive nicotinic receptors in the nucleus accumbens modulate nicotine-stimulated dopamine secretion in vivo. Fu Y; Matta SG; Gao W; Sharp BM Neuroscience; 2000; 101(2):369-75. PubMed ID: 11074160 [TBL] [Abstract][Full Text] [Related]
13. In vivo interactions between α7 nicotinic acetylcholine receptor and nuclear peroxisome proliferator-activated receptor-α: Implication for nicotine dependence. Jackson A; Bagdas D; Muldoon PP; Lichtman AH; Carroll FI; Greenwald M; Miles MF; Damaj MI Neuropharmacology; 2017 May; 118():38-45. PubMed ID: 28279662 [TBL] [Abstract][Full Text] [Related]
14. N-methyl-D-aspartate receptor antagonism in the ventral tegmental area diminishes the systemic nicotine-induced dopamine release in the nucleus accumbens. Schilström B; Nomikos GG; Nisell M; Hertel P; Svensson TH Neuroscience; 1998 Feb; 82(3):781-9. PubMed ID: 9483535 [TBL] [Abstract][Full Text] [Related]
15. Fatty acid amide hydrolase (FAAH) inhibition enhances memory acquisition through activation of PPAR-alpha nuclear receptors. Mazzola C; Medalie J; Scherma M; Panlilio LV; Solinas M; Tanda G; Drago F; Cadet JL; Goldberg SR; Yasar S Learn Mem; 2009 May; 16(5):332-7. PubMed ID: 19403796 [TBL] [Abstract][Full Text] [Related]
16. Metabotropic glutamate 2/3 receptors in the ventral tegmental area and the nucleus accumbens shell are involved in behaviors relating to nicotine dependence. Liechti ME; Lhuillier L; Kaupmann K; Markou A J Neurosci; 2007 Aug; 27(34):9077-85. PubMed ID: 17715344 [TBL] [Abstract][Full Text] [Related]
20. Oleoyl glycine: interference with the aversive effects of acute naloxone-precipitated MWD, but not morphine reward, in male Sprague-Dawley rats. Petrie GN; Wills KL; Piscitelli F; Smoum R; Limebeer CL; Rock EM; Humphrey AE; Sheppard-Perkins M; Lichtman AH; Mechoulam R; Di Marzo V; Parker LA Psychopharmacology (Berl); 2019 Sep; 236(9):2623-2633. PubMed ID: 30993360 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]